DNLI (Denali Therapeutics) Change In Receivables: $0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DNLI Denali Therapeutics Inc DNLI
33 GF Score
Price $25.69
! 6 Warning Signs
View Full Analysis

What is Denali Therapeutics Change In Receivables?

Denali Therapeutics DNLI +5.63% 33 Change In Receivables is $0.00 Mil as of Jun. 2026. GuruFocus rates DNLI with a GF Score™ of 33/100. The stock has 6 warning signs investors should review.

Denali Therapeutics's change in receivables for the quarter that ended in Jun. 2026 was $0.00 Mil. It means Denali Therapeutics's Accounts Receivable stayed the same from Mar. 2026 to Jun. 2026 .

Denali Therapeutics's change in receivables for the fiscal year that ended in Dec. 2025 was $0.00 Mil. It means Denali Therapeutics's Accounts Receivable stayed the same from Dec. 2024 to Dec. 2025 .

Denali Therapeutics's Accounts Receivable for the quarter that ended in Jun. 2026 was $3.93 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Denali Therapeutics's Days Sales Outstanding for the three months ended in Jun. 2026 was 99.43.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Denali Therapeutics's liquidation value for the three months ended in Jun. 2026 was $392.71 Mil.

Denali Therapeutics  (NAS:DNLI) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Denali Therapeutics's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=3.927/3.604*91
=99.43

2. In Ben Graham's calculation of liquidation value, Denali Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Denali Therapeutics's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=710.471-322.777+0.75 * 3.927+0.5 * 4.139
=392.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Denali Therapeutics Change In Receivables Related Terms

Denali Therapeutics Change In Receivables Historical Data

* Premium members only.

The historical data trend for Denali Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Denali Therapeutics Change In Receivables Chart

Denali Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Denali Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
DNLI
33GF Score
Denali Therapeutics Inc DNLI
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Denali Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $0.00 Mil mean?
Denali Therapeutics (DNLI) has a Change In Receivables of $0.00 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Denali Therapeutics and its competitors.
Is Denali Therapeutics' Change In Receivables too high?
Denali Therapeutics' current Change In Receivables is $0.00 Mil. Overall, Denali Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Denali Therapeutics' Change In Receivables compare to RCUS and ALMS?
Denali Therapeutics' Change In Receivables of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Denali Therapeutics and its competitors. Denali Therapeutics's current Change In Receivables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Denali Therapeutics stock overvalued right now?
Denali Therapeutics (DNLI) has a current Change In Receivables of $0.00 Mil. The current Change In Receivables is $0.00 Mil. Denali Therapeutics' overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Denali Therapeutics (DNLI), the current Change In Receivables is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Denali Therapeutics Business Description

Other Exchanges 4DN:GermanyD2NL34:Brazil
Address 161 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
33GF Score

Get the complete analysis for DNLI

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.69
Price